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Characterization of artificially 
re-pigmented ARPE-19 retinal 
pigment epithelial cell model
Laura Hellinen  1, Marja Hagström2, Heidi Knuutila1, Marika Ruponen1, Arto Urtti1,2,3 & 
Mika Reinisalo  1,4
Melanin pigment has a significant role in ocular pharmacokinetics, because many drugs bind at high 
extent to melanin in the retinal pigment epithelial cells. Most retinal pigment epithelial cell lines 
lack pigmentation and, therefore, we re-pigmented human ARPE-19 cells to generate a pigmented 
cell model. Melanosomes from porcine retinal pigment epithelium were isolated and co-incubated 
with ARPE-19 cells that spontaneously phagocytosed the melanosomes. Internalized melanosomes 
were functionally integrated to the cellular system as evidenced by correct translocation of cellular 
Rab27a protein to the melanosomal membranes. The pigmentation was retained during cell 
cultivation and the level of pigmentation can be controlled by altering the amount of administered 
melanosomes. We used these cells to study melanosomal uptake of six drugs. The uptake was 
negligible with low melanin-binders (methotrexate, diclofenac) whereas most of the high melanin-
binders (propranolol, chloroquine) were extensively taken up by the melanosomes. This cell line can 
be used to model pigmentation of the retinal pigment epithelium, while maintaining the beneficial 
cell line characteristics, such as fast generation of cultures, low cost, long-term maintenance and good 
reproducibility. The model enables studies at normal and decreased levels of pigmentation to model 
different retinal conditions.
Retinal pigment epithelium (RPE) is a heavily pigmented cell monolayer between the neural retina and highly 
vascularized choroid. The RPE is essential for the vision, since it maintains photoreceptor viability and function-
ality by phagocytosing shed photoreceptor outer segments1. The RPE also maintains retinoid cycle for photot-
ransduction and protects the retina against solar radiation2. Melanin pigment is synthesized in the RPE cells and 
packed in melanosomes that are pigmented cell organelles3. Most natural melanins are a mixture of brown/black 
eumelanin and yellow/red pheomelanin4. The RPE melanosomes contain mainly eumelanin5,6 whereas melano-
cytes of iris and choroid display varying eumelanin/pheomelanin ratios depending on the iris color7. Melanin 
protects the eye and skin4 against sunlight (including ultraviolet radiation)5,6, scavenges free radicals and main-
tains metal ion homeostasis in the retina7. Melanin is also present in various other tissues in the human body 
(e.g. inner ear and brain). Some disorders cause alterations in the levels of melanin in skin and eye (e.g. forms 
of oculocutaneous albinism)8, whereas other disorders (e.g. ocular albinism, retinitis pigmentosa, age-related 
macular degeneration) specifically reduce the pigmentation in the RPE and other ocular tissues9. Pathological 
conditions associated with altered synthesis of melanin and melanosomes can also affect the homeostasis of the 
eye and visual acuity.
The RPE forms outer blood-retinal barrier that limits the access of drugs and other xenobiotics from the sys-
temic blood stream into the eye. In addition, the RPE is damaged in many ocular diseases (e.g. geographic atro-
phy) that cause impaired vision10. Vision threatening diseases, such as age-related macular degeneration, become 
more common in the aging populations and new drug treatments are needed. The RPE is certainly an important 
drug target and pharmacokinetic barrier.
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Melanin affects ocular pharmacokinetics, because many drugs bind and accumulate to melanin11–16. Recent 
study of >3000 compounds demonstrated that melanin binding is a common feature among drug-like com-
pounds17. Binding of drugs to melanin can lead to prolonged drug action in pigmented ocular tissues18, reduced 
peak responses of drugs19 and drug accumulation into the pigmented ocular tissues20. Overall, the pharmacoki-
netic consequences of melanin binding are a result from a complex interplay between melanin binding and drug 
permeability in the cells16. It is important to understand pigment related pharmacokinetics at cellular level to find 
optimal compounds with prolonged drug action in the retina. Prolongation of drug action and dosing intervals 
are needed in the retinal treatments, because small molecular drugs are otherwise rapidly eliminated after intra-
vitreal injections21.
Lack of proper RPE cell lines hampers development of ocular drugs. Several continuous RPE cell lines are 
commercially available, but they tend to lose the original pigmented phenotype of the RPE16,22. Human RPE cell 
line ARPE-1923 is widely used to study retinal cell biology, pathological conditions and pharmacology, but ARPE-
19 cells lack melanin pigment. Otherwise, ARPE-19 cell line shows appropriate features, such as barrier formation 
and expression of transporters24,25. Considering the pharmacokinetic impact and other functions of melanin in 
the RPE cells, non-pigmented cells are sub-optimal models of the RPE22,26.
Unfortunately, cultures of pigmented primary RPE cells and pigmented stem cell-derived RPE cells are poorly 
reproducible and they require time consuming steps of cell isolation and culture22,27. Therefore, easy-to-use 
RPE-like cell lines would be beneficial in retinal research and drug discovery. Chemicals or optimized culture 
conditions have been used to induce cellular pigmentation22,28, but utilization of phagocytosis of the RPE cells 
seems to be the most efficient and the fastest technique to re-pigment RPE cells. Feeding of melanin or melano-
somes from different sources have been used to re-pigment depigmented cells7,29–32. Nevertheless, viability and 
membrane integrity of the isolated melanosomes have not been studied and, in some cases, the melanosomal 
membrane has been removed before feeding into the cells32. The lack of functional melanosomal membrane com-
promises important melanosomal functions (e.g. ion transport)33,34. Furthermore, intact melanosomal membrane 
is expected to extend the retention of pigment bound drug depot in the cells16.
In this study, we generated artificially pigmented RPE cell model (ARPE-19mel) from commonly used ARPE-
19 cell line by feeding them with isolated porcine RPE melanosomes. Our melanosome isolation technique pro-
duces pure fractions of intact and functional melanosomes with ATPase activity34. Here, we studied the fate of 
melanosomes in the host cells and demonstrated that the melanosomal membrane remains intact after their 
isolation and cellular internalization. Importantly, physiologically relevant pigmentation in the RPE cells was 
achieved. In addition, we determined melanosomal uptake of six drugs that have different affinities to melanin. 
Our cell model enables quantitative control of melanosome quantity in the cells and provides a valuable in vitro 
tool for controlled pharmacological RPE studies.
Results
Melanosome content in ARPE-19mel cells can be controlled. In this work, we generated pigmented 
ARPE-19mel cells by administering isolated porcine melanosomes into regular ARPE-19 cell cultures using the 
method shown in Fig. 1.
Six days after melanosome administration, dose-dependent levels of melanosomes in the ARPE-19mel cells 
were evident (Fig. 2a,b,d–f). Linear correlation between the melanosome dose and resulting melanin amount 
in the cells was demonstrated (Fig. 2b, R2 = 0.9988). This indicates that the melanin content inside the cells 
can be conveniently controlled. The required pigment dose can be estimated with linear regression equation 
(y = 18.025x  −22.84) when the desired pigment content is known (Fig. 2b). The equation can be used if the cells 
are cultured with the same procedures as in this study.
We quantitated the melanin content in the ARPE-19mel cells after culturing them on 96-well plates for 6 days 
after exposing the cells to melanosomes (2.5–204 µg melanin/well) (Fig. 2a). The melanin contents of ARPE-
19mel cells were compared with native, non-cultured porcine RPE (pRPE, Fig. 2a). At the highest melanosome 
dose (204 µg melanin/well), the cellular pigment reached 3700 pg melanin/cell, which is higher than the pigment 
content in the porcine RPE (1110 pg melanin/cell, Fig. 2a). However, when the highest melanosome dose (204 µg/
well) was loaded into the cells three times, no further increase in cellular pigmentation was observed (data not 
shown). Delivering a melanin dose of 68 µg/well to the ARPE-19 cells resulted in equivalent melanin content 
(1180 pg/cell) with freshly isolated porcine RPE cells (1110 pg/cell) (Fig. 2a, Supplementary Table 1). The other 
pigment doses resulted in different levels of cellular melanin (statistical significance: 2.5 µg p = 0.0000014, n = 6; 
7.6 µg p = 0.0000035, n = 6; 22.7 µg p = 0.000024, n = 6; 204 µg p = 0.000025, n = 6). The physiologically relevant 
pigment content was retained in the cells for the culture time (6–7 days), as their calculated pigment recovery was 
approximately 102% (with a range of 63–127%, Supplementary Table 1). Detailed data of the pigment content per 
cell and pigment recoveries are presented in Supplementary material.
Hereafter, we describe the ARPE-19mel cells that were generated with 68 µg melanin/ well. These cells had 
similar melanin content as the primary porcine RPE cells (i.e. marked as 100% pigmentation) (Fig. 2a).
Rab27a translocated into melanosomal membranes. Intracellular localization of melanosomes in the 
cytoplasm of ARPE-19mel cells was seen with transmission electron microscopy (Fig. 3b). No pigmentation was 
seen in the normal ARPE-19 cells (Fig. 3a). After transfection of pigmented ARPE-19mel cells with GFP-Rab27a 
vector, expression and cellular localization of GFP-Rab27a fusion protein was followed by using confocal micros-
copy. Rab27a was localized in the melanosome membrane (Fig. 3c).
Melanin binding of drugs in ARPE-19mel cells. We studied uptake of drugs into melanosomes with 
ARPE-19mel cells displaying different levels of pigmentation. Low melanin-binder drug (pilocarpine) and 
intermediate melanin-binder (timolol) showed lower melanosomal uptake than the high melanin-binders 
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(propranolol, chloroquine) (Fig. 4a–d). Methotrexate and diclofenac are low melanin binders that showed very 
low drug uptake into melanosomes (<5%) (Supplementary material).
There was clear correlation between cellular melanin content and cellular drug uptake (Fig. 4) and differences 
in drug uptake were significant (for statistics, see Supplementary material). Cellular uptake of drugs correlated 
with previously reported in vitro melanin binding values (R2 = 0.829)15,35 (Fig. 4e).
Discussion
In this study, isolated melanosomes from porcine RPE were administered onto human ARPE-19 cell culture 
to re-pigment the cells. The ARPE-19 cells were able to internalize melanosomes at levels corresponding up to 
1180 pg melanin/cell, an amount that is close to the melanin levels in the isolated porcine RPE cells (1110 pg 
melanin/cell, Fig. 2a). At higher melanosome doses, even 3670 pg melanin/cell was reached in the ARPE-19mel 
cells (Fig. 2a). Thus, phagocytosis-based feeding of melanosomes into the ARPE-19 cells was effective, result-
ing in even 3.3-fold higher levels of pigmentation than in the intact porcine RPE. High melanosome levels are 
understandable, since phagocytosis is effective internalization mechanism and cellular melanosome turnover is 
negligible. Melanosomes seem to be stably stored in the cytoplasm of the cells (Supplementary material), and not 
subjected to degradative processes. In our laboratory, the melanosomes in the ARPE-19mel cells retained for at 
least 4 weeks, when the melanosomes were inserted into confluent cell cultures (unpublished observations). This 
finding is similar with the earlier literature describing the artificial re-pigmentation of human RPE cultures with 
isolated melanin33. Consequently, we do not anticipate significant decrease in the cellular pigment content during 
continuous cultivation.
We calculated the theoretical melanin content in the human RPE based on the observed melanin content in 
the porcine RPE cell (1110 pg/cell) and the previously reported cell number in the human RPE (reported range 
2 130 500 to 4 653 200 cells per RPE36, Supplementary Table S1). This calculation corresponded to 2.3–5.1 mg of 
melanin in the human RPE (average 3.9 mg). The total melanin content in the human RPE has not been reported 
previously, but we believe that our estimation is reliable. Previously reported melanin amount in the human 
RPE-choroid was 6.7 mg for individuals with light-colored irides and 8.4 mg for brown-eyed individuals37. The 
choroid may contain more melanin than the RPE and the inter-individual variation in the RPE melanin content 
in normal eyes is low38, but the melanin levels decrease with aging38,39.
Our melanosome isolation method produces intact, functional and pure fraction of melanosomes with proven 
activity of ATPases34. In this study, we characterized the melanosomal membrane of the inserted melanosomes 
inside the cells by overexpressing GFP-Rab27a vector in ARPE-19mel cells. We showed that Rab27a, a melano-
somal membrane protein involved in organelle motility40–43, was sorted to the melanosomal membranes (Fig. 3c) 
indicating that the transferred exogenous melanosomes have functional melanosomal membranes. Intact mela-
nosome membrane is crucial for the functions of the melanosomes, because several proteins responsible for ion 
exchange, melanosomal pH control, and transport of tyrosine are located in the melanosome membranes of the 
Figure 1. Schematic presentation of the ARPE-19mel cell model generation and the melanosomal drug uptake 
assay protocol.
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RPE44. Furthermore, melanosomal membrane has impact on drug distribution from the melanosomes into the 
cytosol, thereby affecting the cellular retention of drugs in pigmented cells16.
Extensive amount of melanin in the RPE45 contributes also to drug accumulation into the cells18,20. 
Drug-melanin interactions play an essential role in ocular pharmacokinetics and toxicity, but as reviewed ear-
lier, drug-melanin interactions have been investigated mostly with isolated or synthetic melanin or isolated 
Figure 2. ARPE-19mel cell model characterization revealed optimal conditions for obtaining physiologically 
relevant stage of pigmentation (a). Melanin content in ARPE-19mel cells 6 days after melanosome dosing. 
The bars display mean values and error bars show standard deviations (SD). Melanosome dose corresponding 
to 68 µg melanin (n = 9) resulted in equal cellular pigmentation as the porcine RPE (n = 8). Other conditions 
resulted in different levels of cellular pigmentation as compared to the porcine RPE (*p < 0.001, n = 6 in each 
condition). The statistical significance was determined with un-paired t-tests using FDR approach (two-stage 
linear step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 1%, without assuming a consistent SD). 
The inset displays porcine RPE (pRPE) and ARPE-19mel pigmentation levels for the cells that were exposed to 
68 µg of melanin per well (i.e. marked as 100% pigmentation levels). (b) Linear correlation between exposed 
melanin amount and cellular pigmentation. Non-pigmented ARPE-19 cells (f) phagocytose isolated porcine 
RPE melanosomes. Melanosomal exposure of the ARPE-19 cells is used to control the pigmentation of the 
ARPE-19mel cells from moderate (e) to heavy pigmentation (d). In ARPE-19mel cells, level of pigmentation 
can be adjusted similar (d) to normal pigmentation of the porcine RPE (c). The cell images (c–f) were obtained 
with regular light microscope. Scale bars: (c) 20 µm, (d) 50 µm, (e) 20 µm, (f) 20 µm.
Figure 3. Melanosomal membrane remains intact during the organelle feeding and internalization to ARPE-
19 cells. Transmission electron microscopy images demonstrate cytoplasmic localization of the melanosomes 
in re-pigmented ARPE-19mel cells (b), but not in normal ARPE-19 cells (a) (both images display 2000x 
magnification and 5 µm scale bars). Endogenously expressed melanosome protein Rab27a in ARPE-19mel 
cells localizes in the membranes of the transferred melanosomes (5 µm scale bar) (c). The inset shows single 
melanosome with enriched GFP-Rab27a protein in melanosome membrane two days after transfection.
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melanosomes16. Such studies inform about the extent and equilibria of melanin binding, but not about the kinet-
ics at cellular level. Therefore, the literature describes drug-melanin interactions without considering organellar 
or cellular environments. Some recent studies have compared the drug uptake into pigmented (cultured porcine 
RPE cells) and non-pigmented (ARPE-19) RPE cells35,46. The compounds with high affinity to melanin had much 
greater cellular accumulation in pigmented than non-pigmented RPE cells (Kp values even 103–104)46. Previous 
simulations also suggest that melanin content is a critical factor that controls cellular kinetics in pigmented cells16. 
The pigment levels in primary RPE cultures decrease rapidly during cell duplication and this factor cannot be 
controlled or prevented. Therefore, control of the melanin content in the cells would be an important experimen-
tal asset, especially for mimicking the changes of pigmentation in the diseased and aging eyes9,38,39.
We quantified melanosomal drug uptake by considering drug accumulation into other cell components and 
culture vessel as background (Eq. 1). Furthermore, other relevant factors, such as active influx or efflux by trans-
porters and metabolic activity, are considered to be identical in ARPE-19 and ARPE-19mel cells. This approach is 
supported by the earlier reports that showed that the pigment binding does not affect the ratio of unbound drug 
inside and outside of the cells (i.e. intracellular bioavailability, Fic)46.
Clear differences in melanosomal drug uptake in the ARPE-19mel cells were seen among six drugs further 
demonstrating the usefulness of these cells. Accumulation into the melanosomes was a dominant factor in cel-
lular uptake for high melanin-binders, since >90% of the administered compound (propranolol, chloroquine) 
resided in the melanosomes (Fig. 4c,d). In contrast, the melanosomal fraction of low melanin-binding drugs 
(methotrexate, diclofenac) was less than 5%. The modest binders (pilocarpine, timolol) had intermediate mela-
nosomal uptake levels (Fig. 4). Correlation between in vitro melanin binding and the melanosomal drug uptake 
in the cells suggests that in vitro binding assays can predict melanin binding in the cells. Larger datasets are, how-
ever, needed to generate predictive models based on chemical structure and melanin binding.
This study proves that melanosome uptake into ARPE-19 cells can be controlled, enabling generation of 
RPE cells with controlled levels of pigmentation (Fig. 2a,b,d–f). The control of pigment content enables cellular 
level studies that quantitate equilibria and kinetics of drug binding to melanin. The model can also be used to 
Figure 4. High melanin-binders propranolol (c) and chloroquine (d) show high melanosomal uptake in the 
ARPE-19mel cells whereas the amounts of low and intermediate melanin binders, pilocarpine (a) and timolol 
(b), in the melanosomes were modest. Melanosomal drug uptake was calculated as: melanosomal drug uptake 
(%) = ( 1 − (CARPE-19mel medium/CARPE-19medium)) * 100%. The drug uptake was studied with 2–6 replicates in each 
condition, and the bars display mean ± SD. Statistical significance (*p < 0.02, ** p < 0.005, ***p < 0.001) of 
the differences was determined using multiple t-tests with FDR approach (two-stage linear step-up procedure 
of Benjamini, Krieger and Yekutieli, with Q = 1%) without assuming a consistent SD (GraphPad Prism 7.04). 
(e) Melanosomal drug uptake in cellular environment correlates with in vitro melanin binding at pH 7.4. 
Melanosomal drug uptake in the cells with 100% melanosome levels was correlated with previously published 
melanin binding percentages in vitro. The data of methotrexate, diclofenac, pilocarpine, propranolol are from15, 
timolol and chloroquine results from35.
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investigate cellular pharmacokinetics in conditions that mimic decreased RPE pigmentation during disease and 
aging. For instance, loss of RPE melanin is associated with age-related macular degeneration9. Indeed, the level 
of pigmentation clearly affects the cellular drug levels (Fig. 4a–d), suggesting that ARPE-19mel cells can be used 
to adjust the melanosome content and mimic different clinical situations. Our cell model could be used as a tool 
in drug discovery when easy-to-use cells are needed in the drug screening programs. Importantly, the active 
transporter profile of ARPE-19 cells is similar with the differentiated human primary RPE cells25, supporting the 
validity of this cell model. ARPE-19mel cells can also be used to study drug retention in the melanosomes and 
profiles of free drug concentrations in the cells.
In conclusion, we described continuously growing and pigmented RPE cell model in which the level of pig-
mentation can be conveniently controlled at relevant levels of melanin. Our drug uptake assay links melanin 
binding with relevant cellular environment, providing an improved tool to assess the kinetic impact of pigment 
binding in the RPE cells. Re-pigmented ARPE-19mel cells can be used to model the clinical differences in the RPE 
pigmentation. Importantly, our cell model contains melanosomes with intact membrane crucial for melanosome 
function and pharmacokinetics. We believe that this cell model will be useful in ocular cell biology, pharmacol-
ogy, toxicology and drug development.
Methods
Overview of the study protocol is presented in Fig. 1.
RPE cell isolation from porcine eyes. Porcine eyes were received from a local slaughterhouse. 
Extraocular tissues, anterior eye segment, vitreous and neural retina were removed with scalpel and tweezers. 
Phosphate-buffered saline (PBS) was added into the eye cup, and the RPE cells were detached by gentle scraping 
with small paintbrush. The cells were collected with a pipet and PBS was removed with centrifugation (6238 g, 
5 min at +4 °C). The RPE cell pellets were stored at −20 °C before isolation of melanosomes or melanin.
Quantitation of melanin content in freshly isolated porcine RPE cells. In order to measure melanin 
content in intact porcine RPE cells (pRPE), freshly isolated pRPE cells were washed by centrifugation, re-suspended 
into PBS and transferred onto 96-well plate. The melanin concentration was measured using absorbance at 595 nm 
(EnVision plate reader, PerkinElmer or Wallac Victor² 1420 Multilabel counter, Perkin Elmer, USA). Melanin 
standards (0.00, 0.05, 0.10, 0.25, 0.50, 1.00 and 2.00 µg melanin/µl) were generated from isolated porcine RPE 
melanin15. Melanin shows a very broad UV-visible absorbance spectrum47, enabling quantitation of porcine RPE 
melanin at wavelengths of 400–600 nm (Supplementary Fig. S1). Melanin quantitation with absorbance method 
has been shown to be consistent with melanin quantitation using HPLC48. After the melanin quantitation, the cells 
were counted with Bürker cell calculation chamber, and melanin amount/cell was calculated.
Melanosome isolation. Intact melanosomes were isolated from porcine RPE as described earlier34 (see the 
original publication for detailed instructions). Briefly, the pRPE cell pellets were thawed on ice, suspended into 
hypotonic buffer (10 Mm Tris-HCl, 10 Mm NaCl, 1.5 mM MgCl2) and lysed with nitrogen cavitation after 15 min 
equilibration at 450 psi (Parr Instruments, chamber was kept on ice during the equilibration). Crude melanoso-
mal fraction was pelleted with 3000 g centrifugation, re-suspended into 10 mM Tris-HCl, 150 mM KCl buffer (pH 
7.40) and layered on top of discontinuous OptiPrep® gradient (bottom-top: 1.5 ml 50%; 1.5 ml 35%; 1 ml 30%; 
1.5 ml 20%; 2.0 ml 15% OptiPrep® solutions). Melanosomal fraction was pelleted at 135 000 g centrifugation 
(SorwallTM WX Ultra Centrifuge, TH-641 Swinging Bucket rotor, Thermo Fischer Scientific), re-suspended into 
10 mM Tris-HCl 150 mM KCl buffer (pH 7.40) and further purified with subsequent OptiPrep® gradient centrif-
ugation. Resulting melanosomal pellet was re-suspended into MES buffer (25 mM MES, 5 mM NaCl, 115 mM 
KCl, 1.3 Mm, pH 7.40) and centrifuged at 10 000 g to remove any residual OptiPrep® solution. The washing step 
was conducted twice, and the melanosomal pellets were stored at −20 °C until further processing. Melanosomal 
melanin content was measured by the spectrophotometry method (A690 nm or 595 nm) as described above.
Cell culture. Non-pigmented ARPE-19 human RPE cell line (CRL-2302, ATCC) was maintained in 
DMEM/12 medium (Gibco BRL 31330-038). The medium was supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin. The cells were grown at +37 °C and 5% CO2.
Re-pigmentation of ARPE-19 cells. Melanosome containing ARPE-19mel cells were generated as 
described below. On day one, ARPE-19 cells were seeded on 96-well plate (20 000 cells/well, equals to 62 500 cells/
cm2). Approximately 24 hours after seeding, different amounts of melanosomes (0, 2.53, 7.58, 22.73, 68.08 and 
204 µg of melanin per well) were applied onto the culture wells as triplicates. Thereafter, the cells were cultured 
for 6–7 days. After melanosome administration, medium was gently renewed once before the analysis, carefully 
avoiding removal of non-phagocytosed melanosomes. In addition to single dose, we tested also repeated delivery 
of melanosomes thrice (3 × 68 µg melanin per well) at intervals of four days.
Quantitation of melanin content in ARPE-19mel cells. Six to seven days after melanosome admin-
istration, cells were washed three times with culture medium to remove non-phagocytosed melanosomes. After 
washing, the growth medium was replaced with PBS and melanin content in the ARPE-19mel cells was quan-
titated with the spectrophotometric method as described above for isolated porcine RPE cells. The standards of 
porcine RPE melanin were added to the non-pigmented ARPE-19 control cells to ensure identical background in 
the standards and test samples. After melanin quantitation, the cells were trypsinized and the number of cells per 
well was counted. Melanin content was normalized to the cell number, resulting in melanin amounts per cell. The 
same procedure was done with intact porcine RPE cells (see above).
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Transmission electron microscopy. Two weeks after melanosome dosing, the cells were fixed and elec-
tron microscopic examination was carried out as described earlier34.
Transfection of ARPE-19mel cells with GFP-Rab27a expression vector. Localization of melano-
somal Rab27a protein was tested by transfecting ARPE-19mel cells with expression vector (GFP-Rab27a) for 
Rab27a protein43 that is fused with green fluorescent protein (GFP). For transfection, ARPE-19 cells were seeded 
on Ibidi µ-Slide (80826, Ibidi) (60 000 cells/cm2). On the following day, single dose of melanosomes (corre-
sponding to 10 µg melanin/well) was given to the cells. Five days later ARPE-19mel cells were transfected with 
GFP-Rab27a plasmid (0.5 µg DNA/well) by using Lipofectamine2000 (P/N100014469 Invitrogen) as a carrier 
according to manufacturer´s instructions. Two days after transfection, expression of the GFP reporter in the cells 
was imaged by using Zeiss LSM800 Airyscan confocal microscope.
Drug uptake studies. Uptake of six different drugs (Table 1) was studied in non-pigmented ARPE-19 cells 
and pigmented ARPE-19mel cells. The melanosome administration was conducted as described above using 
three melanosome doses (corresponding to 7 µg, 20 µg and 68 µg of melanin). These melanosome doses corre-
spond to 10, 30 and 100% levels of pigmentation. The highest external melanosome dose (68 µg) results in similar 
cellular pigmentation with the native pRPE (i.e. normalized as 100%).
Drug uptake study was initiated 4–5 days after melanosome feeding. The experiments were conducted in 
2–6 replicate wells, separately for each compound. The cells were exposed to 4 µM of each drug for 20 hours in 
serum-free culture medium. Then, samples from the medium samples were collected and diluted 2:5 into acetoni-
trile (ACN) with 0.2% formic acid. The samples were centrifuged at 15 000 g for 5 min, and the supernatant was 
collected and diluted 1:10 into mixture of ACN-water (60:40). Finally, internal standards were added at final con-
centration of 100 nM. Different internal standards were used for each compound (Table 1). The melanin amounts 
in the wells were measured after the uptake experiment (see above).
LC-MS/MS. Drugs were quantitated with liquid chromatography mass spectrometry (LC-MS) analyses that 
were carried out with Acquity i-class UPLC (Waters, Massachusetts, USA) coupled with Xevo TQ-S triple quad-
rupole mass spectrometry (Waters). Methods were based on previous studies46,49, with minor modifications. 
Chromatographic separation for all six compounds was carried out using Waters HSS-T3 column (2.1 × 100 mm, 
1.8 µm) and gradient run. The mobile phases were prepared as binary phases. Phase A was purified water with 
0.1% of formic acid and phase B contained 100% lc-ms grade acetonitrile (ChromasolvTM). For pilocarpine and 
methotrexate, the percentage of organic solvent in the gradient solution shifted from 10% to 100% during 3 min-
utes. Total run time was 9 minutes including column flush and stabilization to the initial state. For chloroquine, 
timolol, propranolol and diclofenac, the gradients were similar, but flow rate of 0.4 ml/min was used. Injection 
volumes were 0.25 µl for timolol, 1 µl for propranolol, chloroquine, methotrexate and pilocarpine and 1.5 µl for 
diclofenac. Flow through needle system was used. Column temperature was for methotrexate and pilocarpine 
34 °C and for others 26 °C while sample tray temperature was kept at +10 °C for all samples.
Electrospray ionization on positive mode was used in the analyses. Desolvation temperature was 500 °C and 
desolvation gas flow 1000 l/h for chloroquine and timolol, whereas settings of 600 °C and 900 l/h, respectively, 
were used for the other analytes. Other parameters were identical for all compounds: source temperature 150 °C, 
cone gas flow 150 l/h, nebuliser gas flow 7 bar, collision gas flow 0.15 ml/min. The only exception was the collision 
gas flow for chloroquine (0.25 ml/min). Nitrogen was used as a desolvation gas (Aga, Helsinki, Finland) and 
argon as a collision gas (Aga). Capillary and cone voltages, collision energy and dwell time were tuned individ-
ually for each compound (Table 2). To reach better selectivity we selected two product ions for each compound 
(Table 2) and multiple reaction monitoring (MRM) was used for data recording. Minimum of eight calibration 
curve levels were used for quantification while quality control (QC) samples used to monitor precision and bias 
of the assay. Data were processed with MassLynx V4.1 software (Waters).
Calculation of melanosomal drug uptake. The melanosomal drug uptake was calculated using the Eq. 1 
below:
=



−
−
−


 ×Melanosomal drug uptake
Cmedium ARPE mel
Cmedium ARPE
(%) 1 19
19
100 %
(1)
Compound
pKa, most 
acidic
pKa, most 
basic
logD7.4 
(predicted) Manufacturer Internal standard Manufacturer
pilocarpine — 7.02 −0.4 Santen Oy atenolol-d7 Sigma Aldrich
diclofenac — 4.2 1.4 Sigma Aldrich diclofenac-d4 Toronto Research Chemicals
methotrexate 3.5 5.6 −5.1 Fluka methotrexate-d3 Sigma Aldrich
timolol — 9.4 −0.6 MP Biomedicals rac-timololi-d5 maleate MP Biomedicals
propranolol 13.8 9.5 0.8 Sigma Aldrich rac-propranolol-d7 Toronto Research Chemicals
chloroquine 10.4 — 1.6 Sigma Aldrich chloroquine-d4-phosphate Sigma Aldrich
Table 1. Model compounds and their internal standards and their selected physicochemical properties. pKa and 
predicted logD7.4 values collected from earlier literature46,49, descriptors originally obtained with ACDLabs® Software.
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Statistical testing. Statistical significance of the differences in the melanin content between the generated 
ARPE-19mel cells and freshly isolated porcine RPE cells were evaluated with unpaired t-tests without assuming 
a consistent standard deviation (SD). The p-values were determined with false discovery rate (FDR) approach 
using two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 1%, using GraphPad 
Prism 7.04 software (Fig. 2a). The same statistical method was used to evaluate the influence of pigmentation on 
melanosomal drug uptake (Fig. 3a–d).
Correlation coefficients (Figs 2b, 3f) were obtained with linear regression using GraphPad Prism 7.04 soft-
ware. Residual plots are displayed in the Supplementary material.
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